




PHARMACEUTICAL 2023

Actinium Pharmaceuticals Inc.
Rank 212 of 446





RealRate

PHARMACEUTICAL 2023

Actinium Pharmaceuticals Inc. Rank 212 of 446



The relative strengths and weaknesses of Actinium Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Actinium Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 100%, being 57% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	110,942
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,628
Liabilities, Non-Current	0
Other Assets	2,646
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	37,083
Other Net Income	1,087
Other Revenues	1,030
Property and Equipment	604
Research and Development	23,135
Selling, General and Administrative Expense	11,999

Output Variable	Value in 1000 USD
Assets	114,192
Liabilities	47,711
Expenses	35,134
Revenues	1,030
Stockholders Equity	66,481
Net Income	-33,017
Comprehensive Net Income	-33,017
Economic Capital Ratio	100%